Hyloris Reports Results of Valacyclovir Oral Suspension Under Clinical Evaluation for Herpes Virus Infections
Shots:
- The clinical trial evaluates the relative bioavailability of Valacyclovir Oral Suspension (200 mg/mL) vs Valtrex tablets (50 mg/mL) along with the effect of food on the bioavailability of Valtrex after administration of Valacyclovir in patients with infections caused by Herpes Viruses
- The results from the study depicted a comparably relative bioavailability of Valacyclovir Oral Suspension to Valaciclovir Tablets under fasted conditions. Moreover, based on these results, the company expects to submit an NDA to the US FDA in the year 2024
- Valacyclovir, an antiviral medication, is commercialized in solid oral dosage form across the US to treat herpes virus infections incl. herpes labialis, herpes zoster & herpes simplex in adults & herpes labialis & chickenpox in pediatric patients
Ref: Globenewswire | Image: Hyloris
Related News:- Hyloris Entered into an Exclusive License and Distribution Agreement with AFT Pharmaceuticals for Maxigesic IV in 9 EU Countries
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
